Alkermes Inc. plc

XNASHealth care

Last traded price · USD

$45.91

+0.04%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:47 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $45.89
Volume: 308
Day's high: —
Day's low: —

In brief

Alkermes Inc. plc is a health care company listed on Nasdaq, valued at about $7.70B.
Its shares closed at $45.89 on 4 Nov 2026, up 51.0% over the past year.
From India you can buy ALKS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Alkermes Inc. plc (ALKS) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ALKS share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ALKS options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +10.2% (SPY −1.6%, XLV +13.5%). 3 months: −7.5% (SPY −0.4%, XLV +15.5%). 1 year: +51.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ALKS, SPY and XLV · as of 4 Nov 2026
9.1 days to cover short interest
19.0M shares were sold short at the 15 Oct 2026 settlement, 11.4% of the 167.8M shares outstanding; covering them would take 9.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $45.89 was 4.6% above its 50-day average ($43.86) and 12.8% above its 200-day average ($40.68). It has closed above the 200-day for 15 sessions, since 15 Oct 2026. The 50-day average crossed above the 200-day on 7 Jan 2026, 208 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
66% of the way up its 52-week range
Closed at $45.89 on 4 Nov 2026: 17.6% below the 52-week high of $55.67 (7 Jul 2026) and 70.0% above the low of $27.00 (19 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+10.2%

6 months+29.9%

1 year+51.0%

5 years+51.2%

Newswire

About

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Website

Notable moves

March 31, 2026
+17.28%
February 15, 2024
+16.33%
November 9, 2021
−15.34%

Newswire

About

Website

Notable moves

March 31, 2026
+17.28%
February 15, 2024
+16.33%
November 9, 2021
−15.34%

Alkermes Inc. plc

XNASHealth care

Last traded price · USD

$45.91

+0.04%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:47 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $45.89
Volume: 308
Day's high: —
Day's low: —

In brief

Alkermes Inc. plc is a health care company listed on Nasdaq, valued at about $7.70B.
Its shares closed at $45.89 on 4 Nov 2026, up 51.0% over the past year.
From India you can buy ALKS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Alkermes Inc. plc (ALKS) shares from India?

Do I need the price of a whole ALKS share to invest?

How much can I invest in US stocks in a year?

Can I trade ALKS options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +10.2% (SPY −1.6%, XLV +13.5%). 3 months: −7.5% (SPY −0.4%, XLV +15.5%). 1 year: +51.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ALKS, SPY and XLV · as of 4 Nov 2026
9.1 days to cover short interest
19.0M shares were sold short at the 15 Oct 2026 settlement, 11.4% of the 167.8M shares outstanding; covering them would take 9.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $45.89 was 4.6% above its 50-day average ($43.86) and 12.8% above its 200-day average ($40.68). It has closed above the 200-day for 15 sessions, since 15 Oct 2026. The 50-day average crossed above the 200-day on 7 Jan 2026, 208 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
66% of the way up its 52-week range
Closed at $45.89 on 4 Nov 2026: 17.6% below the 52-week high of $55.67 (7 Jul 2026) and 70.0% above the low of $27.00 (19 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+10.2%

6 months+29.9%

1 year+51.0%

5 years+51.2%

Newswire

About

Website

Notable moves

March 31, 2026
+17.28%
February 15, 2024
+16.33%
November 9, 2021
−15.34%

Newswire

About

Website

Notable moves

March 31, 2026
+17.28%
February 15, 2024
+16.33%
November 9, 2021
−15.34%

Alkermes Inc. plc

Alkermes Inc. plc in brief

Ahead of SPY and its sector fund XLV over 1 year

9.1 days to cover short interest

Above its 50- and 200-day averages

66% of the way up its 52-week range

Alkermes Inc. plc

Alkermes Inc. plc in brief

Ahead of SPY and its sector fund XLV over 1 year

9.1 days to cover short interest

Above its 50- and 200-day averages

66% of the way up its 52-week range